Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 2. Identification of small-molecule inhibitors via coupling with virtual screening

Journal of Medicinal Chemistry

Volumn 48, Issue 9, 2005, Pages 3221-3230

  Toledo Sherman, Leticia ^a,b   Deretey, Eugen ^a   Slon Usakiewicz, Jacek J ^a   Ng, William ^a   Dai, Jin Rui ^a   Foster, J Estelle ^a   Redden, Peter R ^a   Uger, Marni D ^a   Liao, Linda C ^a   Pasternak, Andrew ^a   Reid, Neil ^a  

^a Protana Inc   (Canada)

^b Lymphosign Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPHB2 INHIBITOR; EPHRIN RECEPTOR B2; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ARTICLE; DRUG ACTIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; MASS SPECTROMETRY; PHARMACOPHORE;

ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CHROMATOGRAPHY, AFFINITY; DATABASES, FACTUAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HETEROCYCLIC COMPOUNDS; HUMANS; MASS SPECTROMETRY; MODELS, MOLECULAR; MOLECULAR WEIGHT; NAPHTHOQUINONES; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTOR, EPHB2; SULFIDES;

EID: 20944442425     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0492204     Document Type: Article

References (37)

1. Bolten, B. M.; DeGregorio, T. Trends in Development Cycles. Nat. Rev. Drug Discovery 2002, 1, 335-336.
2. Jorgensen, W. L. The many roles of computation in drug discovery. Science 2004, 303, 1813-1818.
3. Schmid, T. S. Banking on Structures. BioItWorld 2002, October 9.
4. Egan, W. J.; Walters, W. P.; Murcko, M. A. Guiding molecules towards drug-likeness. Curr. Opin. Drug Discovery Dev. 2002, 5, 540-549.
5. Schriemer, D. C.; Bundle, D. R.; Li, L.; Hindsgaul, O. Microscale frontal affinity chromatography with mass spectrometric detection: a new method for the screening of compound libraries. Angew. Chem., Int. Ed. 1998, 37, 3383-3387.
6. Kasai, K. I.; Oda, Y.; Nishikata, M.; Ishii, S. I. Frontal affinity chromatography theory for its application to studies on specific interactions of biomolecules. J. Chromatogr., Biomed. Appl. 1986, 376, 33-47.
7. Chan, N. W. C.; Lewis, D. F.; Hewko, S.; Hindsgaul, O.; Schriemer, D. C. Frontal affinity chromatography for the screening of mixtures. Comb. Chem. High Throughput Screening 2002, 5, 395-406.
8. Chan, N. W. C.; Lewis, D. F.; Rosner, P. J.; Kelly, M. A.; Schriemer, D. C. Frontal affinity chromatography-mass spectrometry assay technology for multiple stages of drug discovery: applications of a chromatographic biosensor. Anal. Biochem. 2003, 319, 1-12.
9. Schriemer, D. C. Biosensor alternative: frontal affinity chromatography. Anal. Chem. 2004, December 1, 440A-448A.
10. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
11. Clark, R. D.; Strizhev, A.; Leonard, J. M.; Blake, J. F.; Matthew, J. B. Consensus scoring for ligand/protein interactions. J. Mol. Graphics Modell. 2002, 20, 281-295.
12. Slon-Usakiewicz, J. J.; Ng, W.; Foster, J. E.; Dai, J.-R.; Deretey, E.; Toledo-Sherman, L.; Redden, P. R.; Pasternak, A.; Reid, N. Frontal affinity chromatography with MS detection (FAC-MS) of EphB2 tyrosine kinase receptor. Part I. Comparison with ELISA. J. Med. Chem. 2004, 47, 5094-5100.
13. Augustin, H. G.; Reiss, Y. EphB receptors and ephrinB ligands: regulators of vascular assembly and homeostasis. Cell Tissue Res. 2003, 314, 25-31.
14. Hafner, C.; Schmitz, G.; Meyer, S.; Bataille, F.; Hau, P.; Langmann, T.; Dietmaier, W.; Landthaler, M.; Vogt, T. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin. Chem. 2004, 50, 490-499.
15. Liu, W.; Ahmad, S. A.; Jung, Y. D.; Reinmuth, N.; Fan, F.; Bucana, C. D.; Ellis, L. M. Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer 2002, 94, 934-939.
16. Tang, X. X.; Brodeur, G. M.; Campling, B. G.; Ikegaki, N. Coexpression of transcripts encoding EPHB receptor protein tyrosine kinases and their ephrin-B ligands in human small cell lung carcinoma. Clin. Cancer Res. 1999, 5, 455-460.
17. Nakamoto, M.; Bergemann, A. D. Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc. Res. Tech. 2002, 59, 58-67.
18. Wu, Q.; Suo, Z.; Risberg, B.; Karlsson, M. G.; Villman, K.; Nesland, J. M. Expression of EphB2 and EphB4 in breast carcinoma. Pathol. Oncol. Res. 2004, 1, 26-33.
19. Zou, J. X.; Wang, B.; Kalo, M. S.; Zisch, A. H.; Pasquale, E. B.; Ruoslahti, E. An Eph receptor regulates integrin activity through R-Ras. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 13813-13818.
20. Adams, R. H.; Wilkinson, G. A.; Weiss, C.; Diella, F.; Gale, N. W.; Deutsch, U.; Risau, W.; Klein, R. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev. 1999, 13, 295-306.
21. Wybenga-Groot, L. E.; Baskin, B.; Ong, S. H.; Tong, J.; Pawson, T.; Sichert, F. Structural basis for autoinhibition of the EphB2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 2001, 106, 745-757.
22. Toledo, L. M.; Lydon, N. B.; Elbaum, D. The structure-based design of ATP-site directed protein kinase inhibitors. Curr. Med. Chem. 1999, 6, 775-805.
23. Traxler, P.; Bold, G.; Frei, J.; Lang, M.; Lydon, N.; Mett, H.; Buchdunger, E.; Meyer, T.; Mueller, M.; Furet, P. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4- D]pyrimidines. J. Med. Chem. 1997, 40, 3601-3616.
24. Levitzki, A. Protein Tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther. 1999, 82, 231-239.
25. Traxler, P.; Bold, G.; Buchdunger, E.; Caravatti, G.; Furet, P.; Manley, P.; O'Reilly, T.; Wood, J.; Zimmermann, J. Tyrosine kinase inhibitors: From rational design to clinical trials. Med. Res. Rev. 2001, 21, 499-512.
26. Taylor, S. S.; Knighton, D. R.; Zheng, J.; Ten Eyck, L. F.; Sowadski, J. M. Structural framework for the protein kinase family. Annu. Rev. Cell Biol. 1992, 8, 429-462.
27. Zhu, X.; Kim, J. L.; Newcomb, J. R.; Rose, P. E.; Stover, D. R.; Toledo, L. M.; Zhao, H.; Morgenstern, K. A. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Struct. Fold Des. 1999, 7, 651-661.
28. Stamos, J.; Sliwkowski, M. X.; Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002, 277, 46265-46272.
29. Kim, S. H.; Schulze-Gahmen, U.; Brandsen, J.; de Azevedo, W. F., Jr. Structural basis for chemical inhibition of CDK2. Prog. Cell Cycle Res. 1996, 2, 137-145.
30. De Azevedo, W. F.; Leclerc, S.; Meijer, L.; Havlicek, L.; Strnad, M.; Kim, S. H. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 1997, 243, 518-526.
31. Gray, N. S.; Wodicka, L.; Thunnissen, A. M.; Norman, T. C.; Kwon, S.; Espinoza, F. H.; Morgan, D. O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S. H.; Lockhart, D. J.; Schultz, P. G. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998, 281, 533-538.
32. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD. Proteins 2003, 52, 609-623.
33. SYBYL, version 6.9; Tripos Inc.: St. Louis, MO (http://www.tripos.com/).
34. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 2000, 43, 3714-3717.
35. Boothe, B.; Zemmel, R. Prospects for productivity. Nat. Rev. Drug Discovery 2004, 3, 451-456.
36. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44, 235-249.
37. Martin, Y. C.; Bures, M. G.; Danaher, E. A.; DeLazzer, J.; Lico, I.; Pavlik, P. A. A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists. J. Comput.-Aided Mol. Des. 1993, 7, 83-102.